[Table_Main] 证券研究报告|行业周报 建筑材料 2024 年 07 月 28 日 建筑材料 中性（维持） 证券分析师 闫广 资格编号：S0120521060002 邮箱：yanguang＠tebon.com.cn 王逸枫 资格编号：S0120524010004 邮箱：wangyf6＠tebon.com.cn 研究助理 市场表现 建筑材料 沪深300 -43% -34% -26% -17% -9% 0% 9% 2023-07 2023-11 2024-03 资料来源：聚源数据，德邦研究所 相关研究 1.《周观点：Q2 建材基金持仓仍维 持低位，静待政策落地后的底部反 转机会》，2024.7.21 2.《建材行业基金持仓点评：建材 板块基金持仓环比再下降，持仓比 例再探新低》，2024.7.19 3.《6 月行业数据点评：地产销售环 比改善明显，高能级城市市场情绪 修复》，2024.7.15 4.《周观点：6 月居民长贷依旧疲 软 ， 水 泥 淡 季 逆 势 提 价 》， 2024.7.14 5.《 中 国 巨 石 （600176.SH）： 24Q2 行业全面复价，公司业绩环比 明显改善》，2024. ...

[Table_Main] 证券研究报告 | 行业周报 食品饮料 2024 年 07 月 28 日 食品饮料 优于大市（维持） 证券分析师 熊鹏 资格编号：S0120522120002 邮箱：xiongpeng＠tebon.com.cn 研究助理 食品饮料 沪深300 2023-05 2023-09 2024-01 -24% -20% -15% -10% -5% 0% 5% 10% 资料来源：聚源数据，德邦研究所 相关研究 1.《百润股份（002568.SZ）：董 事长解除留置，公司生产经营稳定 向好》，2024.5.25 2.《食品饮料行业周报 20240513- 20240517-地产政策密集出台，看 多板块需求反转》，2024.5.19 3.《食品饮料行业周报 20240506- 20240510-24Q1 平稳落地，行业基 本面无虞》，2024.5.12 4.《今世缘（603369.SH）：顺利 跨越百亿，增长势能强劲》， 2024.5.7 5.《口子窖（603589.SH）：业绩 符合预期，改革稳步推进》， 2024.5.6 板块配置回到低位，建议关注 中报超预期个股 食品饮料行业周报 2024072 ...

[Table_Main] 证券研究报告 | 行业深度 汽车 2024 年 07 月 30 日 汽车 优于大市（维持） 证券分析师 邓健全 资格编号：S0120523100001 邮箱：dengjq＠tebon.com.cn 赵悦媛 资格编号：S0120523100002 邮箱：zhaoyy5＠tebon.com.cn 赵启政 资格编号：S0120523120002 邮箱：zhaoqz＠tebon.com.cn 研究助理 秦梓月 邮箱：qinzy＠tebon.com.cn 市场表现 汽车 沪深300 -24% -20% -15% -10% -5% 0% 5% 10% 2023-07 2023-11 2024-03 资料来源：聚源数据，德邦研究所 相关研究 1.《新能源渗透率创新高，上海即将 启动无人驾驶汽车测试》，2024.7.21 2.《萝卜快跑订单爆发式增长， Robotaxi 发展提速》，2024.7.16 3.《6 月乘用车销量环比提升，以旧 换新政策效果逐步显现》，2024.7.8 4.《特斯拉 Q2 交付量超预期，FSD 入华持续推进》，2024.7.7 5.《长安汽车(000625.SZ)：6 月 ...

[Table_Main] 证券研究报告 | 行业点评 房地产 2024 年 07 月 31 日 房地产 优于大市（维持） 证券分析师 金文曦 资格编号：S0120522100001 邮箱：jinwx＠tebon.com.cn 蔡萌萌 资格编号：S0120524050003 邮箱：caimm＠tebon.com.cn 研究助理 房地产 沪深300 -51% -43% -34% -26% -17% -9% 0% 9% 2023-07 2023-11 2024-03 资料来源：聚源数据，德邦研究所 相关研究 1. 《 房 地 产 行 业 周 报 （2024.7.22-7.26）-30 大中城市成 交环比改善，郑州推出首批配售型保 障房》，2024.7.29 2.《三中全会地产相关政策解读-深 化制度改革，加快构建房地产发展新 模式》，2024.7.23 3. 《 房 地 产 行 业 周 报 （2024.7.15-7.19）-北京启动商品房 "以旧换新"，5 年期以上 LPR 调 降》，2024.7.22 4.《滨江集团（002244.SZ）首次覆 盖报告-区域聚焦强品质，业绩稳健 显韧性》，2024.7.17 5. ...

[Table_Main] 证券研究报告 | 行业点评 机器人 2024 年 07 月 31 日 机器人 优于大市（维持） 证券分析师 何思源 资格编号：S0120522100004 邮箱：hesy＠tebon.com.cn 陈瑞基 资格编号：S0120524060002 邮箱：chenrj3＠tebon.com.cn 市场表现 机器人 沪深300 -44% -37% -29% -22% -15% -7% 0% 7% 2023-07 2023-11 2024-03 数据来源：聚源数据，德邦研究所 相关研究 1.《绿的谐波：人形机器人打开谐波 国产龙头第二增长曲线》，2024.2.20 2.《双足机器人腿部设计原则与构型 分类解析》，2024.2.1 3.《博实股份（002698.SZ）： 2023 年度业绩预告略低于预期，后续有望 迎来加速释放》，2024.1.31 4.《2024 机械年度策略报告：新的希 望与周期的力量》，2024.1.5 5.《量产元年，乘势而起--2024 年人 形机器人及智能汽车板块投资策 略》，2024.1.5 机器人板块近期动态点评：英伟 达 GEAR 实验室负责人宣布解 决人形机 ...

[Table_Main] 证券研究报告 | 行业点评 消费电子 2024 年 07 月 31 日 消费电子 优于大市（维持） 证券分析师 陈蓉芳 资格编号：S0120522060001 邮箱：chenrf＠tebon.com.cn 市场表现 消费电子 沪深300 -29% -22% -15% -7% 0% 7% 15% 2023-07 2023-11 2024-03 资料来源：聚源数据、德邦证券研究所 相关研究 1.《兴瑞科技(002937.SZ)：精密镶嵌 注塑行业领军，汽车电子和智能终端 二次腾飞》，2024.7.10 2.《2023 年度报告&2024 年第一季 度报告点评 - 传 音 控 股 （688036.SH）：营收利润大幅增长， 市场份额稳步提升》，2024.4.28 3.《2023 年年度报告及 2024 年 Q1 业绩点评-电连技术（300679.SZ）： 24Q1 单季度利润创历史新高，车载 高 速 连 接 器 龙 头 持 续 超 预 期 》， 2024.4.23 4.《vivo 第三代折叠屏手机发布，华 为 P70 上市在即，手机产业链再迎 高光时刻》，2024.3.31 5.《传音控股 ...

Investment Rating - The report maintains a "Buy" rating for China Tianying (000035.SZ) [2] Core Views - The company has signed a cooperation framework agreement with CRRC Zhuzhou Institute and CRRC Jin控 to jointly develop various forms of new energy projects, enhance equipment order cooperation, and explore new markets [3] - The company expects a significant increase in net profit for the first half of 2024, projected to be between 352 million and 395 million yuan, representing a year-on-year growth of 114.02% to 140.17% [3] - The company's main business in waste incineration is expected to support steady growth, with 20 operational waste-to-energy projects by the end of 2023, processing a total of 21,550 tons of waste per day [3] - The report forecasts steady revenue growth driven by the "Environmental + New Energy" dual-engine development strategy, with projected revenues of 8.743 billion yuan, 11.016 billion yuan, and 13.611 billion yuan for 2024, 2025, and 2026 respectively, reflecting growth rates of 64.2%, 26%, and 23.6% [3] Summary by Sections Market Performance - The current price of the stock is 4.41 yuan, with a total market capitalization of approximately 11.13 billion yuan [2][8] - The stock has experienced a significant decline of 67.4% year-on-year as of 2023 [8] Financial Data and Forecasts - The company anticipates a net profit of 815 million yuan in 2024, with a growth rate of 141.6% compared to 2023 [9][10] - Revenue for 2023 is expected to be 5.324 billion yuan, with a projected increase to 8.743 billion yuan in 2024 [10] - The gross profit margin is expected to stabilize around 24.7% in 2024, with net profit margins improving to 9.3% [10] Cash Flow Analysis - The operating cash flow is projected to increase significantly from 481 million yuan in 2023 to 1.913 billion yuan in 2024 [9] - The net cash flow is expected to turn positive in 2024, reaching 49 million yuan [9] Key Financial Ratios - The report highlights a projected P/E ratio of 13.66 for 2024, indicating a favorable valuation compared to historical performance [10] - The company's return on equity is expected to rise to 8.0% in 2024, reflecting improved profitability [10]

[Table_Main] 证券研究报告 | 公司点评 人福医药(600079.SH) 2024 年 07 月 28 日 买入（维持） 所属行业：医药生物/化学制药 当前价格(元)：18.70 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 吴明华 资格编号：S0120524050002 邮箱：wumh3＠tebon.com.cn 市场表现 -26% -17% -9% 0% 9% 17% 人福医药 沪深300 -34% | --- | --- | --- | --- | |--------------------------------|----------------|--------------|--------| | -43% 2023-07 \n沪深 300 对比 | 2023-11 \n1M | 2024-03 \n2M | 3M | | 绝对涨幅 (%) | 8.47 | -3.56 | -10.15 | | 相对涨幅 (%) | 9.77 | 2.67 | -5.26 | 相关研究 1.《人福医药（600079.SH）：业绩符 合预期，看好 ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company achieved a revenue of 166.77 billion yuan in H1 2024, representing a year-on-year increase of 11.88%, and a net profit of 22.87 billion yuan, up 10.37% year-on-year [5] - The company's global market share for power batteries reached 37.5% in the first five months of 2024, an increase of 2.3 percentage points year-on-year, while the domestic market share was 46.4%, up 3 percentage points year-on-year [5] - The company continues to innovate with new products, including the "Shenxing Plus" battery and the "Kirin" high-power battery, enhancing its competitive edge in both passenger and commercial vehicle segments [5][6] - The company has a robust production schedule for H2 2024, with an expected increase in capacity utilization [6] - Revenue forecasts for 2024-2026 have been adjusted to 417.6 billion, 484.9 billion, and 540.4 billion yuan, respectively, with net profit estimates of 50.9 billion, 59.6 billion, and 70.5 billion yuan, corresponding to P/E ratios of 16x, 14x, and 12x [6] Financial Performance - The company reported a gross margin of 27% in H1 2024, an increase of 5 percentage points year-on-year [5] - The total market capitalization is approximately 832.91 billion yuan, with a total asset value of 715.25 billion yuan [7] - The company’s net profit margin for 2023 is projected at 11.7%, increasing to 13.9% by 2026 [8] Market Comparison - The company's stock performance has shown relative strength against the CSI 300 index, with a 2.35% absolute increase over the past month [3] - The report indicates that the company is expected to outperform the market, with a target price reflecting a significant upside potential [12]

Investment Rating - The investment rating for the company is "Buy (Maintain)" [2] Core Views - The company's performance is under pressure in the short term, but long-term development prospects remain positive [2] - The company reported a revenue of 2.26 billion yuan in the first half of 2024, a decrease of 11.49% year-on-year, and a net profit attributable to shareholders of 265 million yuan, down 3.73% [3] - The company is focusing on compliance marketing and OTC (over-the-counter) development, which is expected to contribute to future growth [3] Financial Performance Summary - The company achieved a revenue of 4.87 billion yuan in 2023, with a projected revenue of 4.88 billion yuan in 2024, indicating a slight increase [5] - The net profit for 2023 was 537 million yuan, with a forecasted net profit of 561 million yuan for 2024 [5] - The gross margin is expected to improve from 74.3% in 2023 to 74.7% in 2024 [6] Research and Development - The company invested 340 million yuan in R&D in the first half of 2024, with an R&D expense ratio of 15.01% [4] - The company has submitted three new drug applications and completed two Phase III clinical studies, indicating a strong pipeline for future products [4] Profit Forecast and Investment Suggestion - The forecast for net profit attributable to shareholders has been adjusted down from 610 million yuan to 560 million yuan for 2024, and from 740 million yuan to 650 million yuan for 2025 [4] - The company is considered a leader in innovative traditional Chinese medicine with a rich pipeline, supporting a long-term positive outlook [4]